Results 201 to 210 of about 2,153,529 (297)

Transcranial Pulse Stimulation Enhances Dexterity in Parkinson's Disease: A Randomized Sham‐Controlled Trial

open access: yesMovement Disorders, EarlyView.
Abstract Background Ultrasound‐based neuromodulation, capable of reaching deep brain areas with high precision, represents cutting‐edge technology in non‐invasive brain stimulation and is investigated as a novel treatment for neurological and psychiatric disorders, including Parkinson's disease (PD).
Eva Matt   +14 more
wiley   +1 more source

Does Neuroglobin Protect Against Stroke? Insights Into the Role of Neurovascular Unit Cells. [PDF]

open access: yesCell Mol Neurobiol
Peinado MÁ   +8 more
europepmc   +1 more source

From Uncertainty to Pathogenicity: Resolving a CSF1R Variant of Uncertain Significance Using Long‐Read Transcriptomics

open access: yesMovement Disorders, EarlyView.
Abstract Background CSF1R‐related disorder (CSF1R‐RD) is a severe autosomal dominant leukoencephalopathy characterized by progressive cognitive, neuropsychiatric, and motor decline. Although genetic testing is widely available, numerous likely pathogenic variants in CSF1R frequently remain classified as variants of uncertain significance (VUS ...
Charles Wade   +8 more
wiley   +1 more source

The GBA1 p.E427K (p.E388K) Variant Is a Risk Factor for Synucleinopathies: A Meta‐Analysis

open access: yesMovement Disorders, EarlyView.
Abstract Background Variants in GBA1 are important genetic risk factors for synucleinopathies, including Parkinson's disease (PD). Although several GBA1 variants are established risk or severity modifiers, the role of the p.E427K variant remains unclear.
Leah V. Chifamba   +30 more
wiley   +1 more source

Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial (OXB‐102/Axo‐Lenti‐PD) in People with Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background SUNRISE‐PD was a dose‐escalating, phase 1/2 study investigating a second‐generation lentiviral vector gene therapy delivering the genes for dopamine synthesis (OXB‐102) to treat Parkinson's disease (PD). The trial was prematurely terminated due to insolvency of the sponsor.
Simon Rowe   +19 more
wiley   +1 more source

Frequency of ZFHX3‐Mediated Spinocerebellar Ataxia 4 in a US Undiagnosed Ataxia Cohort

open access: yesMovement Disorders, EarlyView.
Abstract Background Spinocerebellar ataxia 4 (SCA4) is a late‐onset dominant ataxia with neuropathy caused by exonic GGC repeat expansion in the ZFHX3 gene thought to originate from a Swedish founder event. The GC‐rich expansion is highly thermodynamically stable, posing challenges for standard clinical genetic testing methods.
Annie Chen   +320 more
wiley   +1 more source

Home - About - Disclaimer - Privacy